Week In Review: Nanjing Legend Files To Stage IPO In The US
March 14, 2020 at 19:05 PM EDT
Nanjing Legend Biotech, a subsidiary of GenScript, has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients.
